The BioHub - by Avetix

In this episode of The BioHub by Avetix , I’m joined by Hans Schambye , CEO of BOOST Pharma . Hans shares what drew him to BOOST and the opportunity to develop what could become the first disease-modifying treatment for osteogenesis imperfecta. We discuss the challenge of taking a novel cell therapy from early clinical success towards Phase III, and what it takes to build the company around that j...

We were delighted to be joined by Prakash Raman, Ph. D., CEO of InduPro Therapeutics . Prakash brings more than two decades of experience across the biopharmaceutical industry, spanning business development, licensing, portfolio strategy, venture creation and executive leadership. Before joining InduPro, he was President and CEO of Ribon Therapeutics, following a period as Senior Partner and Chief...

On this episode we're joined by Palisade Bio's CEO & CMO, JD Finley & Mitch Jones. In Q2 2026, Palisade released promising ph1 data for their lead asset - PALI2108 - a PDE4 inhibitor. With recent IND clearance for their ph2 ASCENTRA-UC study, we discuss that data, and what real success looks like clinically & commercially for the business & asset moving forward, in an incre...

In this episode of The BioHub by Avetix , I’m joined by Kristen Wong of Altitude Life Science Ventures . Kristen shares her journey into venture capital and how she thinks about identifying the people and companies worth backing at the earliest stages. We discuss why the investments you pass on can be just as valuable as the ones you make, the importance of founder emotional intelligence, and what...

In this episode we meet Tom Ciulla, CEO of Ikarovec, one of the most exciting gene therapy biotechs in The UK and the ophthalmology scene more broadly. Ikarovec isn't Tom's first rodeo - playing a role in the rise of Iveric, Spark, Viridian, and Nanoscope - but as a first-time CEO, tune in to hear what excited him the most about Ikarovec's bicistronic platform, their plans for clinical trials in G...

In this episode of The BioHub by Avetix , I’m joined by Michael Engsig , CEO of Nykode Therapeutics , and Agnete Fredriksen , Co-Founder and Chief Scientific Officer. Michael and Agnete share the story behind Nykode, how the company’s technology has evolved, and what they’ve learned from building a biotech around a novel approach to immunotherapy. We also discuss the balance between scientific amb...

In this episode of The BioHub Podcast by Avetix, Ben sits down with Dr. David Crean, Chief Business Officer at MediciNova, to explore a career spanning biotechnology, investment, M&A and strategic partnering. The conversation explores David’s journey into biotech, how he evaluates opportunities and partnerships, and the decisions that shape the development of emerging therapeutics. We also dis...

We were delighted to be joined by Kathleen Gallagher, CEO of Atrium Therapeutics. Kathleen has built a fascinating career across the biotech industry, with experience spanning corporate communications, investor relations, clinical development and executive leadership. Before founding Atrium, she spent time at companies including Merrimack Pharmaceuticals and Akcea Therapeutics, before joining Avid...

In this episode of The BioHub by Avetix , I’m joined by Fred Aslan , President and CEO of Artiva Biotherapeutics . Fred shares his journey across venture capital, business development and biotech leadership, including his time at Venrock and Vividion, and how those experiences shaped the way he now leads Artiva. We discuss what it takes to build and scale a biotech, how investor experience changes...

In this episode of The BioHub by Avetix , I’m joined by Luis Peña , Co-Founder, President and CEO of Evommune . Luis shares his journey from scientist to biotech founder, including the story behind building Dermira and the lessons he took from its acquisition by Eli Lilly. We discuss why he decided to start again with Evommune and the company’s ambition to develop new treatments for chronic inflam...

In Q1 of this year, I sat down with Meredith, CFO at Corsera Health, to discuss the future of cardiovascular health and why prediction and prevention are becoming increasingly important in improving outcomes long before a CVD diagnosis. We explored what it takes to build a company at the intersection of science, data and healthcare, how finance and strategy support innovation. A really insightful...

In this episode of the BioHub by Avetix, we’re joined by Dana Watt, Partner at Breakout Ventures, to explore how she evaluates ambitious science-led businesses at the earliest stages. Dana discusses her journey from neuroscience and company building into venture capital, what separates an exciting technology from an investable company, and the signals she looks for in scientific founders. We also...

Todays episode we welcomed Pam Stetkiewicz from Lyora Therapeutics on the BioHub Podcast.

In this episode of The BioHub by Avetix , I’m joined by Handol Kim , Co-Founder and CEO of Variational AI . Recorded at BIO 2026, Handol shares his unconventional journey from more than two decades in technology into biotech, and why he chose to apply generative AI to one of science’s most difficult challenges: discovering new medicines. Variational AI’s Enki platform is purpose-built to generate...

We were delighted to be joined by Ola Włodek, a biotech executive and the CEO of Constructive Bio, a company at the forefront of synthetic biology and the development of new ways to engineer biology and create novel molecules. Ola brings a wealth of experience across the life sciences industry, with a background spanning strategy, operations, and business leadership. At Constructive Bio, she is pa...

In this episode of The BioHub by Avetix, I'm joined by Valerie Vanhooren , CEO and Co-Founder of Ona Therapeutics . Recorded shortly after Ona Therapeutics announced its $85 million Series B , Valerie shares the journey behind building the company, the challenges of fundraising in today's biotech market, and the opportunity to develop next-generation precision oncology therapies that impro...

Paul didn't stumble into biotech, he was pulled in by a diagnosis. When a doctor told his daughter to prepare for a life without her sight due to retinitis pigmentosa, he went all in on finding the best science out there to give patients like her new hope. Today he leads Ray Therapeutics, who're developing optogenetic gene therapies designed to restore vision, not just slow its loss, for patients...

In this episode of The BioHub by Avetix, I'm joined by Samir Ounzain , CEO and Co-Founder of HAYA Therapeutics . Samir shares the journey from pioneering research into the so-called "dark genome" to building one of biotech's most exciting RNA therapeutics companies. We discuss why long non-coding RNAs could unlock an entirely new class of precision medicines, the challenge of turning groundbreakin...

In this episode of The BioHub Podcast, Ben is joined by Tim Noyes, President and CEO of Newleos Therapeutics. Tim reflects on more than 35 years across the life sciences industry, from beginning his career at Merck to building and leading emerging biotechnology companies. He shares why he has consistently been drawn to smaller organisations, where leadership teams can remain close to the science,...

Today we're joined by Ben Swanson , Founder and CEO of Skeletalis , a biotechnology company developing a new generation of precision medicines for bone disease. Ben's path into biotech is anything but conventional. Trained as both a dentist and a scientist, he founded Skeletalis to tackle one of the biggest unmet challenges in musculoskeletal health: how to deliver treatments directly to t...

In this episode of The BioHub Podcast , Max sits down with Bennett Smith, Senior Vice President of Commercial at Beren Therapeutics. Bennett has spent more than two decades building commercial organisations and bringing innovative medicines to patients, holding leadership roles at Novo Nordisk, Regeneron, Akebia, and Orchard Therapeutics, where he helped launch one of the world's most expensiv...

What's the right team to build a precision cardiovascular biopharma company? In this episode Tassos Gianakakos CEO and Chief People Officer Liz Nguyen discuss how Kardigan is thinking about talent, culture, and the capabilities required to bring precision medicine to cardiovascular disease.

In this episode of The BioHub Podcast, Ben sits down with Miles Gerson, Partner at SV Health Investors and Co-Lead of the Dementia Discovery Fund. Miles shares his perspective on investing in neuroscience, building companies around emerging biology and identifying approaches with the potential to change the treatment landscape in dementia and neurodegenerative disease. The conversation explores ho...

In this episode of The BioHub Podcast , Max sits down with Andrew Obenshain, CEO of Inventiva. Andrew brings more than 20 years of experience across global drug development, regulatory strategy, and commercialization. Before joining Inventiva, he led bluebird bio through its transformation into a global commercial-stage gene therapy company and previously held senior leadership roles at Shire and...

Today, I'm delighted to welcome Eduardo, CEO of Citryll Therapeutics. Eduardo has built his career at the intersection of science, innovation, and business, leading the development of transformative therapies designed to address serious autoimmune and inflammatory diseases. With extensive experience in the biotechnology industry, Eduardo has played a key role in guiding companies from scientif...